Global Liver Cancer Diagnostics Market - 2023-2030

Global Liver Cancer Diagnostics Market - 2023-2030

Global Liver Cancer Diagnostics Market reached US$ 8.6 billion in 2022 and is expected to reach US$ 14.1 billion by 2030 growing with a CAGR of 6.6% during the forecast period 2023-2030. Liver cancer is a malignant growth that starts in the liver and can spread to other parts of the body. It is one of the most common types of cancer worldwide. Early diagnosis is key to effectively treating liver cancer.

Currently, there are several diagnostic methods used to diagnose liver cancer. These include imaging tests, such as computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as blood tests that measure levels of certain proteins and hormones. Biopsies can also be performed to collect cells for lab tests. Doctors can effectively detect liver cancer and establish an efficient treatment strategy if they understand the various diagnostic procedures available. Early diagnosis is critical for improving patient outcomes.

Furthermore, the increasing prevalence of liver cancer, rising approvals for novel liver cancer detection tests, and advancement in the imaging systems for liver cancer diagnosis are the factors expected to drive the market over the forecast period.

Market Dynamics

Technological Advancement in the Earlier Detection of Hepatocellular Carcinoma is Expected to Drive the Global Liver Cancer Diagnostics Market Growth

On August 4, 2022, According to new research led by UCLA Jonsson Comprehensive Cancer Centre investigators and involving more than 50 researchers, new technology in development may lead to a better way to detect early-stage hepatocellular carcinoma (HCC), which accounts for 80% to 85% of primary liver cancers and typically occurs in patients with liver cirrhosis or chronic hepatitis B virus. The experimental method analyses and analyses nanoparticles known as extracellular vesicles, or EVs, which are released by normal cells but especially by tumor cells and cells within a tumor microenvironment.

Additionally, UCLA researchers and partners developed a simplified surface protein assay (HCC EV SPA) capable of dissecting and measuring eight HCC EV subpopulations. The scientists believe that the HCC EV SPA technology will one day allow for the quick, highly sensitive, and low-cost identification of early-stage HCC in at-risk patients with liver cirrhosis. It is made up of two powerful platform technologies: proprietary Click Beads for purifying HCC EVs from small volumes of plasma samples, and multiplex, real-time immune-PCR for measurement of HCC EV subpopulations.

Also, the researchers have conducted a Phase 2 biomarker study, following the International Liver Cancer Association biomarker development guideline for detecting early-stage HCC. Therefore, early detection allows physicians and patients to begin therapy sooner, which they believe will have a major influence on survival rates. Thus, owing to the above factors, the market is expected to drive over the forecast period.

The Increasing Prevalence of Liver Cancer is Expected to Drive the Global Liver Cancer Diagnostics Market Growth

According to the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER), Program estimates that 41,210 new cases of liver and intrahepatic bile duct cancer will be diagnosed in the United States in 2023, with some 29,380 people expected to die of primary adult liver cancer. The five-year relative survival rate is just 21.6 percent.

Having hepatitis B, hepatitis C, or cirrhosis are significant risk factors for adult primary liver cancer. Liver cancer is more common in men than women and among Asian/Pacific Islander and American Indian/Alaska Native populations. Therefore, the rising occurrence of liver cancer raises the need for early detection. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Challenges for Obtaining a Tissue Sample for Liver Cancer Diagnosis is Expected to Hamper the Global Liver Cancer Diagnostics Market Growth

Small tumors can be more difficult to biopsy since they may not be immediately visible on imaging investigations or palpable during a physical examination. The smaller the tumor, the more exact the biopsy must be to acquire a sufficient tissue sample for diagnosis.

Complications are possible with liver biopsy procedures, however, they are typically regarded as safe when performed by skilled physicians. However, due to the liver's abundant blood supply, there is a danger of bleeding during or after the biopsy. Other potential risks include infection, harm to neighboring organs, and bile leakage. The likelihood of problems necessitates careful consideration of the dangers vs the advantages of performing a biopsy in each situation.

Thus, owing to the above factors, the market is expected to hamper over the forecast period.

Russia-Ukraine Conflict Analysis

The ongoing conflict between Russia and Ukraine is a geopolitical issue with profound ramifications. Healthcare infrastructure, such as hospitals, diagnostic laboratories, and medical facilities, may suffer damage or be rendered inaccessible in conflict-affected areas. This disruption may affect the availability and accessibility of liver cancer diagnostic services such as imaging technologies, biopsy procedures, and laboratory tests.

Conflicts may interrupt supply chains and reduce the availability of medical supplies such as diagnostic equipment, imaging agents, biopsy tools, and laboratory reagents. This scarcity can cause delays or limits in liver cancer diagnostic techniques, affecting timely and accurate diagnosis.

In addition, the war may cause the displacement of healthcare experts such as radiologists, pathologists, and specialized oncologists, as well as other medical personnel. This loss of expertise may place a further strain on the afflicted regions' liver cancer diagnostic capabilities, perhaps leading to delays in detection and treatment.

Therefore, taking into account the factors mentioned above, it can be stated that the liver cancer diagnostic market experienced a moderate impact as a result of the war.

COVID-19 Impact Analysis:

The COVID-19 pandemic has had an impact on liver cancer diagnosis. COVID-19 can exacerbate existing chronic liver disease and complicate the management of liver cancer. The pandemic has significantly impacted the management of liver cancer patients, from diagnosis to treatment strategies. The modification of screening programs due to COVID-19 has caused delays in liver cancer diagnosis. In a study, 80.9% of participating centers reported a delay in liver cancer diagnosis due to the pandemic.

In contrast, during the COVID-19 pandemic, alternative methods for liver cancer screening have been implemented to adapt to the challenges posed by the healthcare system and to minimize the risk of exposure to the virus. Telemedicine has been widely used during the pandemic to provide remote healthcare services. Virtual consultations allow healthcare providers to assess patients' symptoms, review medical history, and provide guidance on liver cancer screening.

Additionally, risk assessment tools can help identify individuals who are at a higher risk of developing liver cancer. These tools take into account factors such as age, gender, underlying liver disease, and other risk factors. Healthcare providers can use these tools to determine the need for further screening or surveillance.

Segment Analysis

The global liver cancer diagnostics market is segmented based on test type, end user, and region.

Hospitals from the End User Segment Account for 35.52% of the Market Share Owing to the Advanced Imaging Technologies, Integration of Test Results, Increased Diagnostic Testing Demand, and Increasing Number of Hospitals with Imaging Modalities and Screening Facilities.

Hospitals play a vital role in cancer diagnosis, with numerous advantages leading to precise diagnosis and appropriate disease management.

The hospital is equipped with cutting-edge imaging equipment such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scanners.

These cutting-edge diagnostic tests provide detailed, fascinating images of the liver to aid in the diagnosis, characterization, and staging of liver tumors. Specialized tests, such as CT angiography or diffusion-weighted imaging, may be performed in clinical laboratories to examine vascular involvement or detect subtle changes in the tumor.

For instance, Cancer Treatment Centers of America (CTCA) is now the City of Hope, joining forces to expand patient access to personalized, comprehensive cancer care. Moreover, the City of Hope is committed to providing the highest level of care for patients experiencing liver cancer and other gastrointestinal malignancies.

Thus, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 39.6% of the Market Share Owing to the Rising Implementation of Novel Diagnostics, the Presence of Supportive Government Organizations, and Collaborations among Market Players

According to National Center for Biotechnology Information Article 2022, Texas has the highest age-adjusted incidence rate of hepatocellular carcinoma (HCC) in the United States. To address cancer prevention and early detection through research, the Cancer Prevention and Research Institute of Texas (CPRIT) has funded the Texas Collaborative Center for Hepatocellular Cancer (TeCH) to facilitate liver cancer research, education, and advocacy activities. TeCH and its committees facilitate connections and collaborations among HCC researchers and clinicians, healthcare leaders, biotechnology companies, and the public to reduce liver cancer mortality in Texas by 2030.

Additionally, on December 8, 2022, the Department of Veterans Affairs (VA) will research to discover the most efficient screening technique for liver cancer, a lethal malignancy that can be cured if detected early. This is the largest clinical experiment in the history of liver cancer screening. The trial will look into whether finding liver cancer early using a shortened MRI reduces patients' chance of death.

PREMIUM — PREventing Liver Cancer Mortality via Imaging with Ultrasound vs. MRI — the trial's goal is to evaluate whether screening using shortened MRI is better than ultrasound, the current standard of care, in lowering liver cancer fatalities in veterans. VA’s Veterans Health Administration is the largest healthcare provider in the U.S. for patients with cirrhosis, a leading risk factor for liver cancer.

Enrollment will begin in 2023 and follow participants over eight years. This is the first clinical trial to compare the two screening methods for their effect on patient outcomes. Thus, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen N.V., Thermo Fisher Scientific, Inc., Siemens Healthineers, BD, Illumina, Inc., Koninklijke Philips N.V, Epigenomics AG, Fujifilm Medical Systems U.S.A., Inc., and Sysmex Corporation among others.

Why Purchase the Report?
• To visualize the global liver cancer diagnostics market segmentation based on the test type, end user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of liver cancer diagnostics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global liver cancer diagnostics market report would provide approximately 53 tables, 50 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies